Effect of dapagliflozin on blood and breath ketones during supervised insulin withdrawal in adults with type 1 diabetes: A randomized crossover trial
Authors' conclusion
In adults with type 1 diabetes undergoing supervised insulin withdrawal, dapagliflozin treatment compared to usual care was associated with greater blood and breath ketone concentrations in the absence of significant hyperglycaemia.
Study context
- Population
- Adults with T1D undergoing supervised insulin withdrawalcrossover
- Participants
- 20 adults
- Comparison
- Dapagliflozin vs usual care during supervised insulin withdrawal
Methodological detailssupervised insulin withdrawal, Stopping rules: >8 h elapsed, symptoms of ketosis, glucose >400 mg/dL, BOHB >4 mmol/L or participant request
- Supervised insulin withdrawal
- Stopping rules: >8 h elapsed, symptoms of ketosis, glucose >400 mg/dL, BOHB >4 mmol/L or participant request
Primary result
As reported in the abstract
Peak BOHB and BrACE during supervised insulin withdrawal
- Peak BOHB and breath acetone (BrACE) both greater with dapagliflozin than with usual care
- Significantly greater BOHB and BrACE concentrations throughout insulin withdrawal with dapagliflozin
Further findings
Participants reaching BOHB >1.5 mmol/L and >2.5 mmol/L
- Proportions greater with dapagliflozin
Peak blood glucose
- Lower peak blood glucose with dapagliflozin
Original publication
Effect of dapagliflozin on blood and breath ketones during supervised insulin withdrawal in adults with type 1 diabetes: A randomized crossover trial. Diabetes Obes Metab. Published 13 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →